The microtubule as a breast cancer target-Reference-Cited by-同舟云学术

The microtubule as a breast cancer target

Published:2010-09-23 Issue:2 Volume:18 Page:103-119
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Higa Gerald M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12282-010-0224-7.pdf

Reference141 articles.

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

2. Surveillance Epidemiology and End Results. SEER stat fact sheets: breast cancer. SEER Cancer Statistics Review 1975–2005. http://seer.concer.gov/statfacts/html/breast.html . Accessed 7 Apr 2010.

3. Nogales E, Wolf SG, Downing KH. Structure of the αβ tubulin dimer by electron crystallography. Nature. 1998;391:199–202.

4. Rassow J, von Ahsen O, Bömer U, Pfanner N. Molecular chaperones: towards a characterization of the heat-shock protein 70 family. Trends Cell Biol. 1997;7:129–33.

5. Hirata D, Masuda H, Eddison M, Toda T. Essential role of tubulin-folding cofactor D in microtubule assembly and its association with microtubules in fission yeast. EMBO J. 1998;17:667–76.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of benzimidazole-2-amide BNZ-111 as new tubulin inhibitor;Bioorganic & Medicinal Chemistry Letters;2024-11

2. Dual-targeting compounds possessing enhanced anticancer activity via microtubule disruption and histone deacetylase inhibition;European Journal of Medicinal Chemistry;2024-02

3. Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma;International Journal of Molecular Sciences;2023-12-19

4. Recent findings regarding the synergistic effects of emodin and its analogs with other bioactive compounds: Insights into new mechanisms;Biomedicine & Pharmacotherapy;2023-06

5. Investigation of benzimidazole anthelmintics as oral anticancer agents;Bulletin of the Korean Chemical Society;2022-04-08